| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
May 22, 2014Los datos del estudio EVOLVE, presentados hoy en EuroPCR 2014, muestran además un excelente perfil de seguridad.
Boston Scientific Corporation (NYSE: BSX) ha anunciado datos de seguimiento a los tres años del estudio clínico EVOLVE, en el que se comparan la eficacia y el rendimiento del stent coronario...
-
Apr 2, 2014Demonstrating design leadership in drug eluting stent (DES) technology, Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents.
Data from the PLATINUM Workhorse clinical trial were presented by Dean Kereiakes, M.D., F.A.C.C., The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio. The trial compared the safety and...
-
Mar 13, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients
Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's...